The beauty and also possibly the weakness of the strategy (if that’s what they are trying) imho will be proving that A2-73 is the reason for the improvements and not that they just figured out which patients are most likely to benefit from donepezil because it also binds to S1.
It could depend on how many patients in the current trial are only taking A2-73 w/o also taking one of the other SOC’s.
News 
Market Data 
Discover 
